Table 2.
Overview of univariate survival analysis
| Characteristic | DFS | p valuea | OS | p valuea | ||
|---|---|---|---|---|---|---|
| n | Median DFS (95% CI) | n | Median OS (95% CI) | |||
| General characteristics | ||||||
| All patients | 138 | 12.0 (8.8–13.2) | 175 | 27.0 (20.6–33.4) | ||
| Sex | ||||||
| Male | 58 | 11.0 (9.4–12.6) | 0.367 | 82 | 26.0 (9.7–42.3) | 0.768 |
| Female | 80 | 12.0 (8.1–15.9) | 93 | 28.0 (21.6–34.3) | ||
| Age, years | ||||||
| ≤ 60 | 56 | 12.0 (8.2–15.8) | 0.657 | 69 | 28.0 (18.5–37.5) | 0.487 |
| > 60 | 82 | 11.0 (8.7–13.3) | 106 | 27.0 (17.9–36.1) | ||
| ASA classification | ||||||
| I–II | 121 | 12.0 (9.7–14.3) | 0.309 | 150 | 27.0 (20.1–33.8) | 0.171 |
| III | 17 | 9.0 (3.8–14.2) | 25 | 16.0 (8.8–23.2) | ||
| Primary tumor characteristics | ||||||
| Location | ||||||
| Colon | 126 | 12.0 (10.0–14.0) | 0.072 | 159 | 28.0 (21.7–34.3) | 0.237 |
| Rectum | 12 | 6.0 (4.7–7.3) | 16 | 19.0 (2.9–35.1) | ||
| Differentiation | ||||||
| Good/moderate | 110 | 12.0 (9.8–14.2) | 0.918 | 127 | 35.0 (21.6–48.4) | 0.003 |
| Poor/signet cell | 16 | 9.0 (7.2–10.8) | 24 | 9.0 (2.0–16.0) | ||
| Histology | ||||||
| Adenocarcinoma | 117 | 12.0 (9.8–14.2) | 0.301 | 138 | 29.0 (19.3–38.7) | 0.392 |
| Mucinous | 19 | 9.0 (6.2–11.8) | 31 | 23.0 (16.0–30.1) | ||
| T stage | ||||||
| T1–3 | 85 | 11.0 (8.8–13.2) | 0.387 | 107 | 24.0 (15.0–33.0) | 0.918 |
| T4 | 51 | 14.0 (9.7–18.3) | 66 | 29.0 (16.7–41.3) | ||
| N stage | ||||||
| N0 | 53 | 14.0 (6.7–21.3) | 0.181 | 66 | 35.0 (20.6–49.4) | 0.790 |
| N1–2 | 84 | 11.0 (8.9–13.1) | 108 | 24.0 (19.5–28.5) | ||
| Distant metastases | ||||||
| No | 128 | 11.0 (8.7–13.3) | 0.896 | 162 | 28.0 (21.0–35.0) | 0.610 |
| Yes | 10 | 11.0 (2.0–20.0) | 13 | 24.0 (18.4–29.6) | ||
| Stage | ||||||
| Stage 1–2 | 49 | 14.0 (6.1–21.9) | 0.169 | 62 | 35.0 (18.4–51.6) | 0.982 |
| Stage 3–4 | 88 | 11.0 (9.0–13.0) | 112 | 24.0 (19.8–28.2) | ||
| Perioperative treatment | ||||||
| Primary tumor: adjuvant chemotherapy | ||||||
| No | 52 | 12.0 (8.0–16.0) | 0.194 | 64 | 35.0 (22.8–47.2) | 0.658 |
| Yes | 86 | 11.0 (9.3–12.7) | 111 | 24.0 (18.4–29.6) | ||
| Development of PM after primary tumor resection | ||||||
| ≤ 1 year, no chemotherapy | 25 | 20.0 (7.1–32.9) | < 0.001 | 30 | 42.0 (17.7–66.4) | < 0.001 |
| > 1 year, no chemotherapy | 27 | 9.0 (4.5–13.5) | 34 | 24.0 (15.9–32.1) | ||
| ≤ 1 year after chemotherapy | 27 | 6.0 (4.1–7.9) | 36 | 18.0 (11.7–24.3) | ||
| > 1 year after chemotherapy | 59 | 13.0 (10.2–15.8) | 75 | 56.0 (28.9–83.2) | ||
| HIPEC: neoadjuvant chemotherapy | ||||||
| No | 124 | 12.0 (10.0–14.0) | 0.781 | 154 | 27.0 (19.9–34.1) | 0.565 |
| Yes | 14 | 9.0 (5.6–12.4) | 21 | 24.0 (8.6–39.4) | ||
| HIPEC: adjuvant chemotherapy | ||||||
| No | 77 | 11.0 (9.0–13.0) | 0.496 | 102 | 24.0 (12.7–35.3) | 0.167 |
| Yes | 61 | 12.0 (9.6–14.4) | 72 | 28.0 (12.4–43.6) | ||
| Prior surgical score | ||||||
| 0–2 | 129 | 11.0 (8.8–13.2) | 0.577 | 161 | 24.0 (16.8–31.2) | 0.075 |
| 3 | 9 | 21.0 (8.2–33.8) | 10 | Not reached | ||
| HIPEC/PM characteristics | ||||||
| PCI | ||||||
| ≤ 11 | 91 | 13.0 (9.6–16.4) | 0.002 | 94 | 56.0 (–) | < 0.001 |
| > 11 | 46 | 8.0 (4.9–11.1) | 77 | 15.0 (9.4–20.6) | ||
| HIPEC chemotherapy type | ||||||
| Mitomycin C | 126 | 11.0 (9.0–13.0) | 0.649 | 128 | 37.0 (26.3–47.7) | 0.922 |
| Oxaliplatin | 12 | 22.0 (0–51.5) | 13 | 29.0 (–) | ||
ASA American Society of Anesthesiologists, CI confidence interval, DFS disease-free survival, HIPEC hyperthermic intraperitoneal therapy, OS overall survival, PCI Peritoneal Cancer Index, PM peritoneal metastases
aLog-rank test